Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Liabilities and Shareholders Equity (2021 - 2025)

Universe Pharmaceuticals' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $68.0 billion for Q3 2024.

  • For Q3 2024, Liabilities and Shareholders Equity rose 162762.16% year-over-year to $68.0 billion; the TTM value through Sep 2025 reached $68.1 billion, changed 0.1%, while the annual FY2024 figure was $68.0 billion, 162762.16% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2024 was $68.0 billion at Universe Pharmaceuticals, up from $41.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $68.0 billion in Q3 2024 and bottomed at $41.7 million in Q3 2023.
  • The 4-year median for Liabilities and Shareholders Equity is $64.8 million (2021), against an average of $17.0 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity decreased 29.92% in 2023 before it soared 162762.16% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $70.1 million in 2021, then fell by 15.12% to $59.5 million in 2022, then fell by 29.92% to $41.7 million in 2023, then skyrocketed by 162762.16% to $68.0 billion in 2024.
  • Per Business Quant, the three most recent readings for UPC's Liabilities and Shareholders Equity are $68.0 billion (Q3 2024), $41.7 million (Q3 2023), and $59.5 million (Q3 2022).